Net Cash Provided by (Used in) Financing Activities in USD of Tonix Pharmaceuticals Holding Corp. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Tonix Pharmaceuticals Holding Corp. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • Tonix Pharmaceuticals Holding Corp. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $49,533,000.
  • Tonix Pharmaceuticals Holding Corp. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $134,872,000, a 269% increase from 2023.
  • Tonix Pharmaceuticals Holding Corp. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $36,517,000, a 58% decline from 2022.
  • Tonix Pharmaceuticals Holding Corp. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $87,844,000, a 59% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Tonix Pharmaceuticals Holding Corp. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $49,533,000 +$49,745,000 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $212,000 +$11,288,000 +98% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $11,500,000 -$24,563,000 -188% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q1 2022 $13,063,000 -$95,647,000 -88% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q1 2021 $108,710,000 +$79,953,000 +278% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $28,757,000 +$28,684,000 +39293% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $73,000 -$459,000 -86% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q1 2018 $532,000 -$570,000 -52% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q1 2017 $1,102,000 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q1 2013 $0 -$4,237,895 -100% 01 Jan 2013 31 Mar 2013 10-Q 07 May 2013 2013 Q1
Q1 2012 $4,237,895 +$3,934,896 +1299% 01 Jan 2012 31 Mar 2012 10-Q 07 May 2013 2013 Q1
Q1 2011 $302,999 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012 2012 Q1

Tonix Pharmaceuticals Holding Corp. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $134,872,000 +$98,355,000 +269% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $36,517,000 -$51,327,000 -58% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $87,844,000 -$124,643,000 -59% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $212,487,000 +$89,382,000 +73% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
2020 $123,105,000 +$110,186,000 +853% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
2019 $12,919,000 -$10,620,000 -45% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
2018 $23,539,000 +$5,020,000 +27% 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2020 2019 FY
2017 $18,519,000 -$1,979,000 -9.7% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $20,498,000 01 Jan 2016 31 Dec 2016 10-K 09 Mar 2018 2017 FY
2012 $7,492,894 +$4,879,894 +187% 01 Jan 2012 31 Dec 2012 10-K/A 22 Nov 2013 2012 FY
2011 $2,613,000 +$1,220,999 +88% 01 Jan 2011 31 Dec 2011 10-K/A 22 Nov 2013 2012 FY
2010 $1,392,001 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.